Literature DB >> 18333089

Resectable pancreatic cancer: the role for neoadjuvant/preoperative therapy.

Douglas B Evans1.   

Abstract

Entities:  

Year:  2006        PMID： 18333089      PMCID： PMC2020747          DOI： 10.1080/13651820600804005

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN： 1365-182X            Impact factor:   3.647


× No keyword cloud information.
  8 in total

1.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

2.  Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.

Authors:  R A Wolff; D B Evans; D M Gravel; R Lenzi; P W Pisters; J E Lee; N A Janjan; C Charnsangavej; J L Abbruzzese
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

Review 3.  Combined-modality treatment for operable pancreatic adenocarcinoma.

Authors:  Peter W T Pisters; Robert A Wolff; Christopher H Crane; Douglas B Evans
Journal:  Oncology (Williston Park)       Date:  2005-03       Impact factor: 2.990

4.  Borderline resectable pancreatic cancer.

Authors:  Gauri R Varadhachary; Eric P Tamm; Christopher Crane; Douglas B Evans; Robert A Wolff
Journal:  Curr Treat Options Gastroenterol       Date:  2005-10

5.  Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome.

Authors:  Peter W T Pisters; Robert A Wolff; Nora A Janjan; Karen R Cleary; Chusilp Charnsangavej; Christopher N Crane; Renato Lenzi; J Nicolas Vauthey; Jeffrey E Lee; James L Abbruzzese; Douglas B Evans
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

Authors:  D B Evans; T A Rich; D R Byrd; K R Cleary; J H Connelly; B Levin; C Charnsangavej; C J Fenoglio; F C Ames
Journal:  Arch Surg       Date:  1992-11

Review 7.  Neoadjuvant therapy for resectable pancreatic cancer.

Authors:  Chandrajit P Raut; Douglas B Evans; Christopher H Crane; Peter W T Pisters; Robert A Wolff
Journal:  Surg Oncol Clin N Am       Date:  2004-10       Impact factor: 3.495

8.  Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.

Authors:  P W Pisters; J L Abbruzzese; N A Janjan; K R Cleary; C Charnsangavej; M S Goswitz; T A Rich; I Raijman; R A Wolff; R Lenzi; J E Lee; D B Evans
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544
  8 in total
  11 in total

1.  Resectable colorectal liver metastases: optimal sequencing of chemotherapy.

Authors:  Terence C Chua; David L Morris
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases.

Authors:  Ashwani K Singal; William A Ross; Praveen Guturu; Gauri R Varadhachary; Milind Javle; Sathya R Jaganmohan; Ramu P Raju; Jason B Fleming; Gottumukala S Raju; Yong-Fang Kuo; Jeffrey H Lee
Journal:  Dig Dis Sci       Date:  2011-07-13       Impact factor: 3.199

3.  A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.

Authors:  May Piperdi; Theodore P McDade; Joon K Shim; Bilal Piperdi; Sidney P Kadish; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

4.  Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma.

Authors:  Dustin M Walters; Damien J Lapar; Eduard E de Lange; Marc Sarti; Jayme B Stokes; Reid B Adams; Todd W Bauer
Journal:  Ann Surg Oncol       Date:  2011-04-12       Impact factor: 5.344

5.  Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.

Authors:  Susanna W L de Geus; Gyulnara G Kasumova; Mariam F Eskander; Sing Chau Ng; Tara S Kent; A James Moser; Alexander L Vahrmeijer; Mark P Callery; Jennifer F Tseng
Journal:  J Gastrointest Surg       Date:  2017-10-04       Impact factor: 3.452

6.  Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.

Authors:  K Rangarajan; P H Pucher; T Armstrong; A Bateman; Zzr Hamady
Journal:  Ann R Coll Surg Engl       Date:  2019-07-15       Impact factor: 1.891

7.  Imaging in staging and management of pancreatic ductal adenocarcinoma.

Authors:  Raghunandan Vikram; Aparna Balachandran
Journal:  Indian J Surg Oncol       Date:  2010-12-23

8.  Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

Authors:  Lena Schreiber; Ryan Zeh; Christina Monsour; Aslam Ejaz; Allan Tsung; Timothy M Pawlik; Eric Miller; Anne Noonan; Somashekar G Krishna; Heena Santry; Jordan M Cloyd
Journal:  HPB (Oxford)       Date:  2021-10-25       Impact factor: 3.842

9.  Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas.

Authors:  Tiffany A Pompa; William F Morano; Chetan Jeurkar; Hui Li; Suganthi Soundararajan; Jaganmohan Poli; Wilbur B Bowne; Michael Styler
Journal:  Case Rep Oncol Med       Date:  2017-03-08

10.  Clinical predictors of resectability of pancreatic adenocarcinoma.

Authors:  Majid A Almadi; Othman Alharbi; Nahla Azzam; Mohannad Altayeb; Moammed Javed; Faisal Alsaif; Mazen Hassanain; Abdulsalam Alsharabi; Khalid Al-Saleh; Abdulrahman M Aljebreen
Journal:  Saudi J Gastroenterol       Date:  2013 Nov-Dec       Impact factor: 2.485
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.